IVVD

InvivydD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

30%

Probability

Target price

$1.71

+50.0% vs current

Most likely

Base case

45%

Probability

Target price

$1.14

0.0% vs current

B-

Bear case

25%

Probability

Target price

$0.80

-29.8% vs current

AI sentiment snapshot

Latest data as of 2025-09-29

AI commentary

Market tone is cautious-to-constructive: investors price binary clinical risk and funding sensitivity while assigning limited valuation today. Trading shows episodic spikes on news; investor focus remains on readouts and potential partnerships [#CNBC,#PR-2025-07].

RankAlpha Sentiment AI - 2025-09-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

-eventClinical data readoutsHigh impact

Interim or final readouts from INVYMAB programs are binary events that can cause sharp re-ratings; timing is uncertain [#PR],[#10-Q].

-catalystPartnership or licensing dealHigh impact

A strategic collaboration or licensing agreement for INVYMAB could validate the platform and materially re-rate shares [#PR-2025-07].

2025-11-14eventQuarterly results / 10-QHigh impact

Earnings and 10-Q disclosures that clarify revenue, R&D spend, and runway may trigger volatility and funding-related repricing [#10-Qp2].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2025-09-29 • Updated nightlySource: Internal modelMethodology